Tracers / [68Ga]DOTA-MGS8
[68Ga]DOTA-MGS8
Also written as [Ga-68]Ga-DOTA-MGS8
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 1
What it is
- Compound class
- Minigastrin analog (DOTA-conjugated peptide targeting CCK2R)
- Target / mechanism
- Cholecystokinin-2 receptor (CCK2R) PMID 35335396
- Clinical application
- Preclinical characterization for potential PET imaging of CCK2R-related malignancies including medullary thyroid carcinoma (MTC) PMID 35335396
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Scintomics GRP 4V Scintomics | vendor cassette | SPE | 51.7 ± 10.9% yes | 92.2 ± 0.8% | DOTA-MGS8 piCHEM, Raaba-Grambach, Austria | 35335396 2022 Molecules The automated synthesis of [68Ga]Ga-DOTA-MGS8 was performed using a Scintomics GRP4V module (Fürstenfeldbruck, Germany). — corresponding to an average, decay-corrected radiochemical yield of 51.7 ± 10.9% |
Need this precursor?We can point you to suppliers for [68Ga]DOTA-MGS8, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 35335396. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 35335396: 'DOTA-MGS8'. Stage set/updated at stage 23 from PMID 35335396: 'preclinical studies were carried out to characterize the targeting potential'.